AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03723616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Only
Description: Participants will view at random 24 ads twice, each ad will have a different health warning chosen at random with the caveat that each health warning will be seen 3 times. The 16 control ads will have text disclaimers to control for physical features of the ads.
Study NCT03723616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text + Graphic
Description: This arm is identical to the text only intervention except a graphic will be added to the health warning. Thus, each ad will be seen twice; the text + graphic warnings will be seen three times. The 16 control ads will have text disclaimers and logos or other images to control for physical features of ads.
Study NCT04154436 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water (H2o)
Description: Alkaline Solution
Study NCT03339700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 4800mg/m2, intravenous (IV), divided 4 days, 1200mg/m2/day, during days -5 to -2
Study NCT03910504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.3 mg*kg
Description: Patients randomized to the control group will receive rocuronium at 0.3 mg\*kg ev bolus at the induction of anesthesia.
Study NCT03910504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Rocuronium
Description: Patients randomized to the interventional group will not receive neuromuscular blockade at the induction of anesthesia.
Study NCT01906333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01906333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Study NCT01906333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasted
Study NCT04325971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Description: MR, EEG recordings
Study NCT03339700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7 to -4.
Study NCT03339700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 80mg/kg, intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.
Study NCT04458506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary expansion
Description: Correction of the unilateral posterior cross bite in children
Study NCT03339700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
Study NCT04458506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary expansion
Description: Correction of the unilateral posterior cross bite in children
Study NCT01733173 — intervention group
Intervention type: PROCEDURE
Intervention: MRI with DTI and fMRI
Description: When possible, the subject will undergo a post operative fMRI/ DTI scan as well as clinical language testing. If the subject develops CMS, the second fMRI will be performed as soon as possible. Some subjects may be severely impaired or have difficulty performing fMRI and clinical language testing tasks. In these instances, the fMRI and language testing may not be performed, or we may choose to perform resting state or passive fMRI tasks instead.
Study NCT05351684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 MG
Description: already included in arm/group descriptions.
Study NCT00997035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing \<40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.
Study NCT00997035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.
Study NCT03694405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Booster vaccination with MenACWY-CRM
Study NCT00689585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250mg matching placebo capsules
Study NCT00689585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Description: 500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
Study NCT00189488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Administered as an intravenous (IV) bolus.
Study NCT03694405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-DT
Description: Booster vaccination with MenACWY-DT
Study NCT00189488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an intravenous (IV) bolus.
Study NCT00189488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: Each participant received 1 of the following conditioning regimens:~* Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)~* TBI/VP-16~* Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie > 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)~* Busulfan (Bu)/Cy~* Bu/Mel (non-TBI but fully ablative regimens/doses \[Mel dose > 140 mg/m\^2\])~* Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses \[Mel dose > 140 mg/m\^2\])
Study NCT00189488 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conditioning Regimen
Description: Each participant received 1 of the following conditioning regimens:~* Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)~* TBI/VP-16~* Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie > 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)~* Busulfan (Bu)/Cy~* Bu/Mel (non-TBI but fully ablative regimens/doses \[Mel dose > 140 mg/m\^2\])~* Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses \[Mel dose > 140 mg/m\^2\])
Study NCT00189488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplant
Description: Allogeneic marrow/peripheral blood progenitor cell transplantation
Study NCT00189488 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic stem cell transplant
Description: Allogeneic marrow/peripheral blood progenitor cell transplantation
Study NCT03694405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Description: Booster vaccination with MenACWY-TT
Study NCT02204930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PeproStat
Description: A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
Study NCT01138423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Once daily treatment with aliskiren for 8-weeks, according to the following regiment: once daily (morning time) 150 mg during the first 2 weeks, followed by once daily (morning time) 300 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 150 mg on day 1, 2, 3, 4, 5 and 7.
Study NCT01138423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: Once daily treatment with moxonidine for 8-weeks, according to the following regiment: once daily (morning time) 0.2 mg during the first 2 weeks, followed by once daily (morning time) 0.4 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 0.2 mg on day 1, 2, 3, 4, 5 and 7.
Study NCT01138423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Once daily treatment with hydrochlorothiazide for 8-weeks, according to the following regiment: once daily (morning time) 12.5 mg during the first 2 weeks, followed by once daily (morning time) 25 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 12.5 mg on day 1, 2, 3, 4, 5 and 7.
Study NCT01138423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for aliskiren)
Description: Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
Study NCT01138423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for aliskiren)
Description: Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
Study NCT01138423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for moxonidine and hydrochlorothiazide)
Description: Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
Study NCT01138423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for moxonidine and hydrochlorothiazide)
Description: Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
Study NCT03382886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered as a 240mg IV infusion given once every two weeks (+/- 3 days).~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity
Study NCT03382886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered as an IV infusion from 1-10mg/kg in accordance with the appropriate subject cohort being examined as described below:~Dose level 1: 5 mg/kg intravenously once every two weeks Dose level 2: 10 mg/kg intravenously once every two weeks Dose level -1: 1 mg/kg intravenously once every two weeks~Dosing is based on actual body weight. There is no dose adjustment for obese or frail individuals. Dosing is recalculated if patient weight changes by more than 10% as reviewed by the principal investigator.~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity
Study NCT00725777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Description: Standard artemether-lumefantrine treatment
Study NCT01026012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
Study NCT01342913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate 100mcg/Vilanterol 25mcg
Description: Inhalation Powder
Study NCT01342913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticaosne Propionate 500mcg/Salmeterol 50mcg
Description: Inhalation Powder
Study NCT02426333 — intervention group
Intervention type: OTHER
Intervention: Abiraterone Acetate
Description: Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)
Study NCT00923923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stress
Description: compare levels of stress
Study NCT02869633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given by mouth
Study NCT02869633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04024891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate Ophthalmic Solution 1%
Description: 1% phentolamine mesylate ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Study NCT04024891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Description: Topical Sterile Ophthalmic Solution
Study NCT00189488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00189488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Study NCT01772446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS MESSAGING
Description: SMS MESSAGING TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED DIABETES
Study NCT01764685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Max therapeutic dose of 150mg/day
Study NCT01764685 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management
Description: Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
Study NCT04098523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Duplex ultrasound
Description: A one-time carotis and abdominal aorta duplex ultrasound will be performed on-site by a skilled site staff to determine the prevalence of, and risk factors associated with, CAS and AAA. A diameter measurement will be performed of the abdominal aorta as well as a determination of the carotid arteries.
Study NCT00359463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eltrombopag
Description: Subjects will be administered a single oral dose of 50 mg eltrombopag.
Study NCT00359463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Subjects will be administered a single oral dose of 50 mg eltrombopag.
Study NCT01764685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
Study NCT01764685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01015339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 infusion,d1,d8 every 3 weeks
Study NCT01015339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
Study NCT01494948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: allergen challenge
Description: nasal challenges with antigen to which they are sensitive to
Study NCT01494948 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: allergen challenge
Description: nasal challenges with antigen to which they are sensitive to
Study NCT04149249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention Video Doctor
Description: Complete CONNECT: participants will undergo in-person assessment questions and follow-up assessment questions. They will view and participate in the interactive Video Doctor about Smoking Cessation.
Study NCT04149249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Intervention no Video Doctor
Description: Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources.
Study NCT02018341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: homeopathic remedy in 30C potency
Study NCT01015339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
Study NCT01015339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 80mg/m2, day 1 of every 3 weeks
Study NCT04029194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistance with old age pension application
Description: The intervention will offer elderly assistance in applying for the old age pension.
Study NCT04362384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E ovules
Description: Endoanal vitamin E ovules will be prescribed
Study NCT04362384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone ointment
Description: Endoanal Prednisolone ointment will be prescribed
Study NCT02717351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-07)
Study NCT01262677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
Study NCT01262677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
Study NCT01262677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
Study NCT01262677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
Study NCT01262677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
Study NCT01262677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched to the active drug
Study NCT03805347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Helminthostachys zeylanica(L.)Hook
Description: Extract of Helminthostachys zeylanica(L.)Hook, 1gm/time, 3 times daily
Study NCT03805347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Description: Starch in capsule, 1gm/time, 3 times daily
Study NCT02018341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01772966 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Spinal manipulation
Study NCT01772966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Study NCT00972101 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 3 Gy of radiation on Days -7,-6, -5 and -4.
Study NCT00847925 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Avotermin (RN1001)
Description: 100ul/linear cm of wound. Dosed before surgery and 24h later